Literature DB >> 9593835

The role of mu and kappa opioid receptors within the periaqueductal gray in the expression of conditional hypoalgesia.

P S Bellgowan1, F J Helmstetter.   

Abstract

The periaqueductal gray (PAG) is a midbrain structure involved in the modulation of pain and expression of classically conditioned fear responses. Non-selective opioid antagonists applied to the PAG block the expression of hypoalgesia in rats exposed to a Pavlovian signal for shock. This study was conducted to determine the anatomical and pharmacological specificity of the PAG's role in conditional hypoalgesia. Rat subjects received injections of either the mu opioid antagonist CTAP (6.6 nMol), the kappa opioid antagonist Nor-binaltorphimine (Nor-BNI, 6.6 nMol) or saline. Injections were made into either the dorsolateral (dlPAG) or ventrolateral (vlPAG) PAG prior to the presentation of an auditory stimulus that had previously been paired with foot shock while measuring nociception with the radiant heat tail flick (TF) test. Elevation in TF latency in response to the auditory stimulus was blocked only by administration of CTAP into the vlPAG. These results suggest that conditional hypoalgesia (CHA) is subserved by mu but not kappa opioid receptors located in the vlPAG but not the dlPAG. Copyright 1998 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593835     DOI: 10.1016/s0006-8993(98)00057-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

Review 1.  Macromolecular synthesis, distributed synaptic plasticity, and fear conditioning.

Authors:  Fred J Helmstetter; Ryan G Parsons; Georgette M Gafford
Journal:  Neurobiol Learn Mem       Date:  2007-10-31       Impact factor: 2.877

2.  Neurobiology of placebo effects: expectations or learning?

Authors:  Marta Peciña; Christian S Stohler; Jon-Kar Zubieta
Journal:  Soc Cogn Affect Neurosci       Date:  2013-07-24       Impact factor: 3.436

Review 3.  Central modulation of pain.

Authors:  Michael H Ossipov; Gregory O Dussor; Frank Porreca
Journal:  J Clin Invest       Date:  2010-11-01       Impact factor: 14.808

4.  Blockade of endogenous opioid neurotransmission enhances acquisition of conditioned fear in humans.

Authors:  Falk Eippert; Ulrike Bingel; Eszter Schoell; Juliana Yacubian; Christian Büchel
Journal:  J Neurosci       Date:  2008-05-21       Impact factor: 6.167

5.  A feedback neural circuit for calibrating aversive memory strength.

Authors:  Takaaki Ozawa; Edgar A Ycu; Ashwani Kumar; Li-Feng Yeh; Touqeer Ahmed; Jenny Koivumaa; Joshua P Johansen
Journal:  Nat Neurosci       Date:  2016-11-14       Impact factor: 24.884

Review 6.  Mechanisms of placebo analgesia: A dual-process model informed by insights from cross-species comparisons.

Authors:  Scott M Schafer; Stephan Geuter; Tor D Wager
Journal:  Prog Neurobiol       Date:  2017-11-03       Impact factor: 11.685

7.  Drug response profiles to experimental pain are opioid and pain modality specific.

Authors:  Lindsay L Kindler; Kimberly T Sibille; Toni L Glover; Roland Staud; Joseph L Riley; Roger B Fillingim
Journal:  J Pain       Date:  2010-12-13       Impact factor: 5.820

8.  Yin-and-yang bifurcation of opioidergic circuits for descending analgesia at the midbrain of the mouse.

Authors:  Jong-Hyun Kim; Gireesh Gangadharan; Junweon Byun; Eui-Ju Choi; C Justin Lee; Hee-Sup Shin
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-08       Impact factor: 11.205

9.  Interaction of auditory and pain pathways: Effects of stimulus intensity, hearing loss and opioid signaling.

Authors:  Senthilvelan Manohar; Henry J Adler; Kelly Radziwon; Richard Salvi
Journal:  Hear Res       Date:  2020-06-04       Impact factor: 3.208

Review 10.  Engaging endogenous opioid circuits in pain affective processes.

Authors:  Blake A Kimmey; Nora M McCall; Lisa M Wooldridge; Theodore D Satterthwaite; Gregory Corder
Journal:  J Neurosci Res       Date:  2020-12-13       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.